Transcenta has entered a strategic collaboration and non-exclusive licensing agreement with EirGenix to deploy Transcenta’s Highly Intensified Continuous Bioprocessing platform across EirGenix’s biologics development and manufacturing operations. The deal includes access to continuous perfusion and integrated hybrid continuous purification technologies, paired with process documentation and regulatory support. Transcenta will receive an upfront payment, milestones, and royalties tied to commercial use. EirGenix plans to apply the platform both for its internal pipeline and as a differentiating offer to CDMO clients seeking intensified and continuous manufacturing.
The move elevates continuous bioprocessing from pilot projects to a monetizable, transferable platform business model. The strategic question is no longer whether continuous can work at scale, but who will own the know-how, standardize regulatory pathways, and capture the economics as biologics cost pressures intensify. By licensing a full-stack process with embedded regulatory packages, Transcenta is turning manufacturing excellence into an asset class, while EirGenix is positioning to win sponsors who require lower COGS, tighter process control, and geopolitical supply chain optionality.
This matters now because the economics of biologics are under simultaneous pressure from payer pushback, tender dynamics, and the coming wave of high-volume modalities. Continuous approaches promise higher productivity, smaller footprints, and improved lot-to-lot consistency versus fed-batch, which can translate into meaningful COGS reductions. For payers, a credible path to lower manufacturing costs strengthens pricing and access discussions, especially in competitive categories like biosimilars and oncology antibodies. For patients and health systems, lower COGS can expand availability in cost-sensitive markets and support broader indication expansion. For HCPs, greater reliability and consistency mitigate supply disruptions that have plagued biologics in recent years.
For competitors, the implications are twofold. First, CDMOs that lack a validated continuous offering risk being boxed out of programs where sponsors are designing for manufacturing from day one. Second, a non-exclusive license model accelerates diffusion: if Transcenta establishes the de facto playbook for continuous perfusion and hybrid purification with regulatory-ready documentation, the barrier to adoption shifts from technology to execution and client acquisition. This could compress margins for late adopters while favoring CDMOs capable of rapid tech transfer, PAT integration, and real-time release strategies aligned with ICH Q13 principles.
The collaboration also intersects with broader industry trends. Biotech financing constraints are forcing platform monetization beyond the clinic, and manufacturing IP is emerging as a tradable asset akin to expression systems. Continuous manufacturing has strong regulatory tailwinds, and sponsors are seeking supply chains diversified away from perceived geopolitical risk. EirGenix, as Taiwan’s largest biologics CDMO, can use continuous capability to court Western programs seeking both cost efficiency and jurisdictional resilience. On the modality front, intensified mAb production supports the expanding ADC pipeline, where antibody supply is a gating factor, and could be critical as large-scale cardiometabolic biologics drive unprecedented demand.
Execution will determine whether this becomes a template. Demonstrating robust control strategies, comparability for post-change products, and credible case studies will be essential to win global sponsors and payer recognition of COGS advantages. The open question for 2026 and beyond is whether intensified and continuous processing becomes the default for new mAbs and ADC backbones—and who ultimately captures the value: the platform licensor, the CDMO, or the sponsor negotiating price in markets where tender frameworks absorb efficiency gains.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
